Abstract
Background: Combination PARPi plus WEE1i (PARPi + WEE1i) induces replication stress (RS), DNA damage, and abrogates the G2 cell cycle checkpoint. Concurrent PARPi + WEE1i administration effectively inhibits tumor growth but is poorly tolerated. Sequential PARPi+WEE1i administration in vivo mirrors concurrent dosing in cells with high basal RS, while normal cells with low basal RS are protected from DNA damage, improving tolerability while preserving efficacy (Fang et al., Cancer Cell 2019). Based on these compelling preclinical data, the NCI CTEP-sponsored STAR study investigated sequential ola+ada in pts with DDR aberrant advanced tumors (NCT04197713).
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call